ANN ARBOR, MI — Oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) gained Food and Drug Administration approval in 2012, and many commentators hailed the therapy as a “once-in-a-generation” advance.
HOUSTON — After a decade of dramatically rising rates of hepatocellular carcinoma (HCC) among veterans, aggressive treatment of hepatitis C infections (HCV) appears poised to turn the tide.
SEATTLE — Pulmonary infections remain more common in patients with human immunodeficiency virus (HIV), compared with those who are uninfected. Surmising that an increase in chronic lung diseases among aging HIV positive patients could contribute to the risk, a University… Read More
Pre-infection Immunological Health Achieved in Some Cases By Annette M. Boyle SAN ANTONIO — For years, clinicians have not recommended treating human immunodeficiency virus (HIV) patients with antiretroviral therapy (ART) before they saw a significant drop in T-cell levels. Starting… Read More
Subhead: Post-operative Mortality Rates Low Among ART Users By Annette M. Boyle WEST HAVEN, CT — Historically, high post-operative mortality rates among HIV-infected patients caused many physicians and patients to defer or avoid surgery all together. For today’s veterans with… Read More
Raymond Schinazi, PhD, Hon DSc, still remembers how the patients lined the corridors. They were all too thin, too pale and much too weak.
Amid all the outcry over the high cost of new hepatitis C therapies, including congressional hearings, a simple fact has been overlooked: The VA expects to save money in the long run because of the drugs’ high cure rates. By… Read More
Alliance Research Not Limited by Private-Sector Restraints By Annette M. Boyle BETHESDA, MD – In celebration of its second anniversary, the John P. Murtha Cancer Center at the Walter Reed National Military Medical Center, announced plans to substantially expand its… Read More